BioCentury | Jul 9, 2012

Triple play in diabetes

The addition of Amylin Pharmaceuticals Inc. 's glucagon-like peptide 1 franchise will give partners Bristol-Myers Squibb Co. and AstraZeneca plc three modern mechanisms in their commercial diabetes portfolio and five in the pipeline - more than...
BC Week In Review | Feb 13, 2012
Clinical News

AC165198: Phase I started

Amylin disclosed in its 4Q11 earnings that in January it began a Phase I trial to evaluate AC165198. Amylin and Biocon are jointly developing and commercializing AC165198 under a 2009 deal (see BioCentury, Sept. 14,...
Items per page:
1 - 2 of 2